What question did this study set out to answer?

December 8, 2025BloodOpen Access

Healthcare costs associated with hematopoietic cell transplant for sickle cell disease in the United States and Canada: A comparative analysis

View Full Paper

Ask AI

Bookmark

Authors

Comparative analysis reveals cost effectiveness and healthcare utilization differences in sickle cell disease treatments in the US versus Canada.

This study aims to compare the healthcare costs associated with hematopoietic cell transplant for sickle cell disease between the US and Canada.
Retrospective data collection from financial datasets of three healthcare centers, two from the US and one from Canada.
Eligibility included children and young adults who received hematopoietic cell transplants from matched sibling donors.
Cost data categorized into clinical care, laboratory, diagnostic imaging, and pharmaceutical costs.
Median cost per patient of HCT was similar in both countries, with US at $130,604 and Canada at $107,925.
Significant differences in clinical, imaging, and pharmacy costs were identified between the US and Canada.
Pharmaceutical costs showed substantial variation, influenced by different healthcare financing and pricing systems.

Gharial et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Comparative analysis reveals cost effectiveness and healthcare utilization differences in sickle cell disease treatments in the US versus Canada.